5 Best Cancer Stocks to Buy for the Long Term

We recently compiled a list of the 10 Best Cancer Stocks to Buy for the Long Term. If you wish to see the complete list, visit 5 Best Cancer Stocks to Buy for the Long Term.

5. AstraZeneca PLC (NYSE:AZN)

Number of Hedge Fund Holders: 52

AstraZeneca PLC (NYSE:AZN) is among the best cancer stocks on this list.

TheFly reported on May 6 that CDT Equity announced that AZD5904, a selective inhibitor of human myeloperoxidase originally licensed from AstraZeneca PLC (NYSE:AZN), has entered the Patent Cooperation Treaty stage, expanding its potential for international intellectual property protection. The compound has been evaluated across five Phase 1 clinical studies involving 181 participants, where it showed an acceptable safety profile with no clear drug-related adverse effects reported.

The company also highlighted supporting patent coverage, including composition-of-matter and method-of-use protections related to idiopathic male infertility, backed by preclinical findings. CDT is also exploring broader applications in oncology-associated infertility and is actively pursuing partnerships to advance further development and commercialization opportunities.

Separately, earlier on May 1, an FDA oncology advisory panel noted a positive benefit–risk assessment for AZN’s Truqap when used with abiraterone and androgen deprivation therapy for patients with PTEN-deficient metastatic hormone-sensitive prostate cancer, based on results from the CAPItello-281 Phase III study. The panel vote supported the evaluation, reflecting a strong consensus.

Trial data showed a reduction in disease progression or death risk and a meaningful extension in radiographic progression-free survival compared with standard therapy plus placebo. Additional secondary endpoints also favored the combination, including delayed resistance and fewer skeletal complications. Overall survival data remain immature as the study continues.

AstraZeneca PLC (NYSE:AZN) is a global biopharmaceutical company headquartered in Cambridge, focused on oncology. It develops a broad portfolio of cancer treatments targeting lung, breast, ovarian, and blood cancers, aiming to advance science-led therapies across multiple platforms.